Interstitial Lung Disease
Tool predicts new-onset exertional, resting hypoxemia in patients with fibrotic ILD
A tool that includes age, BMI, two lung function measures and a diagnosis of idiopathic pulmonary fibrosis can predict new-onset exertional and resting hypoxemia in fibrotic interstitial lung disease, according to study results.
Q&A: Improving ILD diagnosis times through physician education
Increasing health care worker awareness of interstitial lung diseases can have a major impact on the timing of this diagnosis and receipt of treatment for suffering patients.
Celltrion submits application for Actemra biosimilar to FDA
Celltrion USA has submitted a Biologics License Application to the FDA for its tocilizumab biosimilar candidate CT-P47, according to a press release.
FDA has yet to confirm Yutrepia for pulmonary hypertension-ILD
The FDA did not meet its Prescription Drug User Fee Act goal date that would extend Yutrepia as a treatment for patients with pulmonary hypertension associated with interstitial lung disease, according to a press release.
Palliative telecare team improves quality of life in COPD, ILD
Receiving care from a palliative telecare team resulted in more improvements in quality of life than usual care among patients with COPD, interstitial lung disease or heart failure, according to study results published in JAMA.
Consuming omega-3 fatty acids may reduce pulmonary fibrosis progression
In patients with pulmonary fibrosis, consuming omega-3 fatty acids may improve diffusing capacity for carbon monoxide and lengthen survival, according to results published in CHEST.
Severe OSA linked to poorer lung function over time
Over time, adults with severe obstructive sleep apnea had more high attenuation areas on CT and lower lung function, which may signal early interstitial lung disease, according to data published in Annals of the American Thoracic Society.
VIDEO: Investigating phenotypes of rheumatoid arthritis-associated interstitial lung disease
SAN DIEGO — In this Healio video, Jeffrey A. Sparks, MD, MMSc, highlighted studies from members of his group at Brigham and Women’s Hospital that were presented at ACR Convergence 2023.
ILD treatment differs by sex, race across countries
The prevalence of patients with interstitial lung disease who receive treatment varied across countries, with some sex- and race-based differences, according to results published in CHEST.
VIDEO: TNF inhibitors appear safe for patients with RA-associated ILD
SAN DIEGO — Kathryn Dao, MD, discusses a study presented at ACR Convergence 2023 that compared the initiation of TNF inhibitors with non-TNF inhibitor biologics or JAK inhibitors among patients with rheumatoid arthritis-associated interstitial lung disease.